# A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

> **NCT04322708** · PHASE2,PHASE3 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 277 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **OTHER:** Placebo
- **DRUG:** lirentelimab (AK002)

## Key facts

- **NCT ID:** NCT04322708
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2021-06-04
- **Final completion:** 2022-01-18
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322708, "A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04322708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*